Applied Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Applied Therapeutics (Nasdaq: APLT), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. The company will take part in:

• The Baird 2024 Global Healthcare Conference with a fireside chat on September 10, 2024, at 3:45 p.m. ET in New York, NY
• The 2024 Cantor Global Healthcare Conference with a presentation on September 18, 2024, at 10:20 a.m. ET in New York, NY

Live webcasts for both events will be available on the company's website under the Investor Relations section. Replays will be archived for 90 days following each event. Applied Therapeutics focuses on developing novel drug candidates for indications with high unmet medical needs.

NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the company will participate in the following upcoming investor conferences:

• Baird 2024 Global Healthcare Conference: Fireside chat on Tuesday, September 10, 2024, at 3:45 p.m. ET in New York, NY
  
• 2024 Cantor Global Healthcare Conference: Presentation on Wednesday, September 18, 2024, at 10:20 a.m. ET in New York, NY.
  

Live webcasts for the events will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay of the webcasts will be archived on the Company’s website for 90 days following the event.

About Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.

To learn more, please visit www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx.

Contacts

Investors:
Julie Seidel/Andrew Vulis
646-970-0543
appliedtherapeutics@argotpartners.com

Media:
media@appliedtherapeutics.com

FAQ

When is Applied Therapeutics (APLT) participating in the Baird 2024 Global Healthcare Conference?

Applied Therapeutics (APLT) is participating in the Baird 2024 Global Healthcare Conference with a fireside chat on Tuesday, September 10, 2024, at 3:45 p.m. ET in New York, NY.

What time is Applied Therapeutics (APLT) presenting at the 2024 Cantor Global Healthcare Conference?

Applied Therapeutics (APLT) is presenting at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 a.m. ET in New York, NY.

Where can investors access the webcasts of Applied Therapeutics' (APLT) conference presentations?

Investors can access the live webcasts of Applied Therapeutics' (APLT) conference presentations on the Events page under the Investor Relations section of the company's website at www.appliedtherapeutics.com.

How long will the replays of Applied Therapeutics' (APLT) conference presentations be available?

Replays of Applied Therapeutics' (APLT) conference presentations will be archived on the company's website for 90 days following each event.